Johnson & Johnson (JNJ) Total Current Liabilities (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Current Liabilities of $57.7 billion for Q1 2026, up 6.63% sequentially from $54.1 billion in Q4 2025, and up 1.43% YoY from $56.9 billion in Q1 2025.
Johnson & Johnson (JNJ) Total Current Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson (JNJ) has 18 years of Total Current Liabilities data on file, last reported at $57.7 billion in Q1 2026.
- Quarterly Total Current Liabilities rose 1.43% year-over-year to $57.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.7 billion (up 1.43% YoY) and the FY2025 annual result came in at $54.1 billion, up 7.56% from the prior year.
- Total Current Liabilities rose to $57.7 billion in Q1 2026 per JNJ's latest filing, from $54.1 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $60.4 billion in Q2 2023, with the low at $43.4 billion in Q2 2022.
- Average Total Current Liabilities over 5 years is $51.0 billion, with a median of $51.3 billion recorded in 2024.
- Year-over-year, Total Current Liabilities soared 39.14% in 2023 and decreased 19.29% in 2024.
- Johnson & Johnson's Total Current Liabilities stood at $45.5 billion in 2022, then increased by 1.62% to $46.3 billion in 2023, then rose by 8.73% to $50.3 billion in 2024, then grew by 7.56% to $54.1 billion in 2025, then increased by 6.63% to $57.7 billion in 2026.
- Business Quant data shows JNJ's Total Current Liabilities at $57.7 billion in Q1 2026, $54.1 billion in Q4 2025, and $50.9 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 36.63 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 57.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 42.10 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -32.57 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 26.95 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 24.96 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 9.48 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 34.35 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 3.00 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 57.72 Bn |
| Dec 28, 2025 | 54.13 Bn |
| Sep 28, 2025 | 50.87 Bn |
| Jun 29, 2025 | 54.18 Bn |
| Mar 30, 2025 | 56.90 Bn |
| Dec 29, 2024 | 50.32 Bn |
| Sep 29, 2024 | 51.76 Bn |
| Jun 30, 2024 | 53.93 Bn |
| Mar 31, 2024 | 48.73 Bn |
| Dec 31, 2023 | 46.28 Bn |
| Oct 1, 2023 | 44.37 Bn |
| Jul 2, 2023 | 54.17 Bn |
| Apr 2, 2023 | 60.37 Bn |
| Jan 1, 2023 | 55.80 Bn |
| Oct 2, 2022 | 45.54 Bn |
| Jul 3, 2022 | 44.82 Bn |
| Apr 3, 2022 | 43.39 Bn |
| Jan 2, 2022 | 45.23 Bn |
| Oct 3, 2021 | 44.56 Bn |
| Jul 4, 2021 | 38.72 Bn |